This population-based cohort study quantifies the association between proton pump inhibitor use and incident chronic kidney disease among participants in the Atherosclerosis Risk in Communities study.
This decision-analytic model of treatment for hepatitis C virus genotype 1 assesses the cost-effectiveness of treating all patients with hepatitis C virus infection at all stages of fibrosis vs those with advanced fibrosis only in a US treatment-naive population sample.
MacLaren et al evaluate the occurrence and risk factors for gastrointestinal hemorrhage, pneumonia, and CDI in critically ill patients. Gross provides an Invited Commentary.
Li et al evaluate the association between sildenafil use and risk of incident melanoma among men in the United States. See also the invited commentary by Robinson.
Sacks and coauthors report a case of long-term management of intractable near-fatal recurrent pancreatitis secondary to severe hypertriglyceridemia by a novel use of lomitapide, an inhibitor of microsomal triglyceride transfer protein, recently approved for treatment of familial homozygous hypercholesterolemia.
This retrospective nationwide population study conducted using data from the Taiwan National Health Insurance Research Database investigates the incidence of, risk factors for, and mortality associated with allopurinol hypersensitivity in new users of allopurinol.
Dunkler et al evaluate the association between diet; alcohol, protein, and sodium intake; and incidence or progression of chronic kidney disease among individuals with type 2 diabetes mellitus. See also the invited commentary by Kramer and Chang.
O’Hare et al extrapolate a treatment effect from randomized clinical trials for prevention of end-stage renal disease (ESRD) to a real-world population of older patients with chronic kidney disease. See the Invited Commentary by Tinetti.